Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
The Highland-Stoner Hill neighborhood in Shreveport, Louisiana deserves accurate, unexaggerated information about GLP-1 therapy — not the marketing version, but the actual peer-reviewed clinical data and a physician who honestly evaluates your health profile before prescribing. RealityPeptides shows every Highland-Stoner Hill patient the exact trial numbers up front: semaglutide 14.9% over 68 weeks (STEP 1, NEJM 2021), tirzepatide up to 22.5% over 72 weeks (SURMOUNT-1, NEJM 2022). These are what the controlled trials documented — not what the best-case testimonial claimed.
For Highland-Stoner Hill patients, the documented timeline is straightforward: initial measurable weight loss begins at weeks 4–8 after reaching maintenance dose. Maximum outcomes are reached at 12 to 18 months of consistent therapy. Your FDA-approved medication ships from a PCAB-accredited pharmacy to any Highland-Stoner Hill address within 2–5 business days. Regular telehealth check-ins track your progress against the trial benchmarks — transparently, not optimistically.
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 4, 2026
Landmark randomized controlled trials in the New England Journal of Medicine establish the efficacy profile of FDA-approved GLP-1 medications available to Highland-Stoner Hill, Shreveport residents:
Telehealth prescribing of GLP-1 receptor agonists in Louisiana is conducted by board-certified, -licensed physicians through HIPAA-compliant platforms. GLP-1 medications are not DEA-scheduled controlled substances and may be prescribed via telehealth after a valid clinical evaluation.
1,961 adults with obesity or overweight randomized to semaglutide 2.4 mg weekly vs. placebo. At 68 weeks, the semaglutide group achieved a mean 14.9% body weight reduction, compared to 2.4% in the placebo group. 86.4% of semaglutide patients lost at least 5% of body weight. 69.1% lost at least 10%. 50.5% lost at least 15%. These are the documented facts for Highland-Stoner Hill patients considering semaglutide.
2,539 adults with obesity randomized to tirzepatide (5, 10, or 15 mg weekly) vs. placebo over 72 weeks. Mean weight reductions by dose: 5 mg = 15%, 10 mg = 19.5%, 15 mg = 20.9%. The highest-dose group's mean was 22.5%. 91% of 15 mg patients lost at least 5% of body weight. Currently the highest-documented efficacy of any FDA-approved GLP-1 agent — a fact Highland-Stoner Hill patients can use to make an informed choice.
Trial averages are population means — they are not guarantees or individual predictions. Roughly half of trial participants in Highland-Stoner Hill-equivalent conditions did better than the average; half did less. Your board-certified physician at RealityPeptides will review your actual BMI, metabolic history, and health data to give you a personalized projection anchored in the trial evidence, not in the headline number that the industry uses as a marketing tool.
The documented trial figures for Highland-Stoner Hill patients: semaglutide produced a 14.9% average body weight reduction over 68 weeks (STEP 1, NEJM 2021, n=1,961). Tirzepatide produced up to 22.5% in the highest-dose group over 72 weeks (SURMOUNT-1, NEJM 2022, n=2,539). Liraglutide produced approximately 8% over 56 weeks (SCALE trial). These are population averages from peer-reviewed trials — your board-certified physician will give you an honest, personalized projection for your specific starting profile in Highland-Stoner Hill, not the best-case number from the brochure.
Initial measurable weight loss for Highland-Stoner Hill patients typically occurs within 4–8 weeks after reaching the effective maintenance dose. The full trial-documented outcomes — the 14–22% benchmarks — are reached at 12 to 18 months. Many patients in Highland-Stoner Hill experience a normal plateau around months 4–6 that can be discouraging; your physician will walk you through the documented progression curve at intake so you know what to expect and stay on course throughout the full protocol.
Complete our online health intake with your real medical history, current medications, and weight goals. A board-certified physician will review your actual health data — not an algorithm — and give you a frank, evidence-based assessment of which GLP-1 medication fits your profile and what documented outcomes the trials support for your starting point. If approved, your FDA-approved medication ships to any Highland-Stoner Hill address within 2–5 business days from a PCAB-accredited pharmacy. No inflated promises, no surprises — just the data and a plan built on it.
Local weight loss and GLP-1 providers serving the Highland-Stoner Hill, Shreveport area, based on Google Business listings.
3532 Youree Dr Suite A
(318) 250-0070
5/5 ★ (41 reviews)
2551 Greenwood Rd Suite 320
(318) 212-6940
4.9/5 ★ (34 reviews)
Bossier City, LA
(318) 746-3880
4.9/5 ★ (367 reviews)
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
